Next 10 |
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
2024-06-18 09:01:00 ET More on Merck Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Tran...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...
2024-05-29 09:55:22 ET Summary Agenus Inc. is developing botensilimab and balstilimab for colorectal cancer, among other oncology indications. The company's timeline for a Biologics License Application filing for BOT/BAL in CRC has been delayed, but an FDA meeting in July could be...
2024-05-24 13:32:38 ET More on Agenus, Ligand Pharma, etc. Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation Agenus Inc. (AGEN) Q1 2024 Earnings Call Transcri...
2024-05-20 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem befor...
2024-05-07 23:03:10 ET Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Conference Call May 07, 2024 04:30 PM ET Company Participants Michael Jeong - Investor Relations Todd Davis - Chief Executive Officer Paul Hadden - Senior Vice President, Investmen...
2024-05-07 16:52:18 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earning...
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference cal...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...